In fact, all genetic mouse models describing tumor suppressive activity of AMBRA1 so far have been generated on a mutated KRAS/BRAF/MAPK signaling background, and mutations of the KRAS/BRAF/MAPK pathway are common in DLBCL, LUAD, and melanoma [77, 78]. This evidence concerns the gene BRAF and diffuse large B-cell lymphoma.